Sign In
Buy MBIO
$0.741
-0.0201 (-2.64%)
At Close: Jun 03, 2026
Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More
01:53pm, Saturday, 26'th Dec 2020
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying c
Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
07:30am, Monday, 07'th Dec 2020
Data presented at the 62 nd American Society of Hematology (ASH) Annual Meeting show extremely favorable safety profile and clinical activity
Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
08:00am, Tuesday, 01'st Dec 2020
Call to be held Wednesday, December 9, 2020, at 1:00 p.m. EST Call to be held Wednesday, December 9, 2020, at 1:00 p.m. EST
Mustang Bio Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights
04:20pm, Friday, 06'th Nov 2020
WORCESTER, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in
Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting
09:25am, Wednesday, 04'th Nov 2020
WORCESTER, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in
7 Cutting-Edge Biotech Stocks for Tomorrow
08:59am, Wednesday, 28'th Oct 2020
Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.
Mustang Bio: Slow, Steady Progress Towards Multiple Gene And CAR-T Therapy Goals
02:52pm, Tuesday, 25'th Aug 2020
Mustang, like its Parent company Fortress Bio, licenses promising drug candidates from research and medical institutions.
Mustang Bio (MBIO) Investor Presentation - Slideshow
12:13pm, Friday, 21'st Aug 2020
The following slide deck was published by Mustang Bio, Inc. in conjunction with this event..
Do Options Traders Know Something About Mustang Bio (MBIO) Stock We Don't?
12:53pm, Tuesday, 18'th Aug 2020
Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.
WORCESTER, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs
Oppenheimer: These 3 Penny Stocks Could Rally Over 100%
07:31pm, Wednesday, 12'th Aug 2020
Weighing in on the markets from investment firm Oppenheimer, chief investment strategist John Stoltzfus believes that despite rough conditions, the market has more fuel left in the tank. Remaining “
Mustang Bio Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
08:30pm, Monday, 10'th Aug 2020
WORCESTER, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs
Celyad Oncology annoncera prochainement les résultats financiers du premier semestre 2020 et tiendra une conférence téléphonique
12:00am, Monday, 03'rd Aug 2020
Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq : CYAD), une société de biotechnologie de stade
Mustang Bio (MBIO) Looks Good: Stock Adds 5.8% in Session
12:52pm, Tuesday, 21'st Jul 2020
Mustang Bio (MBIO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Mustang Bio (NASDAQ:MBIO) Downgraded by Zacks Investment Research
06:36pm, Wednesday, 15'th Jul 2020
Mustang Bio (NASDAQ:MBIO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com report
